Investing

0 140
Puma Biotechnology Inc PBYI Stock News

Puma Biotechnology (NASDAQ: PBYI) is off to an incredibly strong start in the pre-market hours this morning, and for good reason. The FDA has approved a treatment submitted by the company. Of course, this led to excitement among investors, causing gains and prompting our partners at Trade Ideas to alert us to the movement. At the moment (9:08), PBYI is trading at $93.40 per share after a gain of 8.48% thus far today.





PBYI Rockets On FDA Approval

As mentioned above, Puma Biotechnology is having a strong start to the trading session this morning after news that the FDA has approved an experimental treatment hit center stage. The treatment that was approved is known as neratinib, a drug designed for the treatment of breast cancer. In particular, the drug is designed to reduce the risk of breast cancer recurrence after initial treatment.




Neratinib is a treatment that proves to be the first of its kind. Designed to treat early-stage breast cancer with the HER2 genetic mutation where the tumor has been surgically removed and that has been treated with Herceptin, the treatment has proven to be effective in keeping cancer away.

The data in the NDA showed that 94.2% of patients that were treated with neratinib didn’t experience any recurrence of cancer or death. This was compared to 91.9% of patients who were given a placebo. While that may seem like a relatively small difference, this is great news for those fighting breast cancer, as it gives them further hope of the ability to ward off any recurrence of cancer after treatment.

For PBYI, neratinib is a big deal. After all, breast cancer is the most frequently diagnosed form of cancer in women. Out of all women that are diagnosed with breast cancer, 20% to 25% of them are diagnosed with HER2-positive breast cancer. So, there is ultimately an incredibly dire need for a treatment like this as it will address a massive population of patients. For PBYI, that simply means that demand for this treatment will likely be strong.

In a statement, Richard Pazdur, Director of the FDA Oncology Center of Excellence, had the following to offer with regard to the newly approved PBYI treatment:

HER2-positive breast cancers are aggressive tumors and can spread to other parts of the body, making adjuvant therapy an important part of the treatment plan… Now, these patients have an option after initial treatment that may help keep the cancer from coming back.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on PBYI. In particular, we’re interested in following the story of neratinib, and excited to see what the company does as they move to the commercial phases. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Advanced Micro Devices, Inc. AMD Stock News

Advanced Micro Devices, Inc. (NASDAQ: AMD) isn’t off to the best of starts in the pre-market hours this morning, and for good reason. The stock was hit by a big downgrade, leading to fear among investors and pushing the value of the stock toward the bottom. Of course, our partners at Trade Ideas were the first to alert us to the declines. At the moment (8:40), AMD is trading at $13.27 per share after a loss of $0.53 per share (3.84%) thus far today.





Barclays Downgrades AMD

As mentioned above, Advanced Micro Devices isn’t having the best of times in the pre-market hours this morning after Barclays made the decision to downgrade the stock. Barclays Analyst Blayne Curtis downgraded the stock from equal weight to underweight. In the process, the analyst cut the price target to $9 per share, saying it will reach this mark within a year. That’s a 35% implied downside and the target is 31% below the consensus average of $13.01 per share. So, what’s the big deal?




One of the big issues here is that the market is currently pricing AMD based on expectations of many that the company will take a large chunk of Intel’s market share. While a slice may be taken out of Intel by AMD, the analyst believes that there’s not going to be enough to cause the company to maintain its exorbitant price.

Another big factor here has to do with the cryptocurrency boom that recently took place. After all, Bitcoin and Ether miners must use high-end technology in order to efficiently do their work. However, Wall Street is warning that the cryptocurrency boom could run out of steam relatively soon, and that’s bad news for AMD. After all, cryptocurrency values are starting to fall, and when prices fall, mining isn’t quite as lucrative.

So, the idea here is that AMD has a price that includes expectations of continued growth in demand thanks to cryptocurrency mining as well as an expectation of Advanced Micro Devices taking a large chunk of Intel’s market share in this space. However, the analyst behind the downgrade simply doesn’t believe that this is the case.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AMD. In particular, we’re interested in following the company to see if a demand shortage does start to take place as cryptocurrency prices fluctuate. However, we believe that various key factors were left out of the expectations here. Perhaps, the most important of these factors is that AMD is likely to take a large chunk of Intel’s market share in the data center industry. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Netflix, Inc. NFLX Stock News

Netflix, Inc. (NASDAQ: NFLX) is off to an incredibly strong day in the market today, and for good reason. The company reported its earnings after the closing bell yesterday, beating expectations in various categories and exciting investors. Of course, this excitement led to gains, prompting our partners at Trade Ideas to alert us to the movement. At the moment (8:14), NFLX is trading at $176.20 per share after a gain of $14.50 per share (8.97%) thus far today.





NFLX Reports Second Quarter Earnings

As mentioned above, Netflix is off to an incredible start in the market this morning, and for good reason. The company reported results from the second quarter, and while earnings per share slightly missed the mark, revenue and subscriber growth definitely picked up the slack. Here’s what we saw from the earnings report:




  • Earnings Per Share – In terms of earnings per share, NFLX slightly missed the mark. During the quarter, analysts were expecting that the company would report earnings in the amount of $0.16 per share. However, the company actually reported earnings in the amount of $0.15 per share, falling a penny behind expectations.
  • Revenue – While earnings slightly missed the mark, that wasn’t the case when it comes to revenue. During the quarter, analysts expected that NFLX would generate revenue in the amount of $2.76 billion. However, the company reported total revenue in the amount of $2.78 billion.
  • The Big Story – Sure, financial data came in slightly below or slightly above expectations. So, what’s the big story? Well, the big story here is subscriber growth. During the second quarter, Netflix said it added a total of 5.2 million streaming subscribers. That figure absolutely blew Wall Street expectations away. In fact, Wall Street was expecting subscriber growth to come in at 3.2 million for the quarter. In the third quarter, NFLX expects to bring in 4.4 million new subscribers. This is also well ahead of analyst estimates of 3.99 million.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on NFLX. In particular, we’re interested in following the growth in subscribers that the company has been able to amass. Nonetheless, we’ll continue to follow the story and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Camber Energy Inc CEI Stock News

Camber Energy Inc (NYSEMKT: CEI) is having an incredible day in the market today. However, if you look at company specific news, well, there isn’t any. So, why is CEI finding its way toward the top? Before we get into that, we’d like to thank our partners at Trade Ideas for being the first to alert us to the gains. At the moment (11:18), CEI is trading at $0.37 per share after a gain of $0.06 per share or 18.64% thus far today.





CEI Gains As Natural Gas Prices Head Up

The reason for the gains we’re seeing on CEI at the moment is a relatively simple one. First and foremost, it starts with the company’s flagship product, natural gas. You see, natural gas was on a losing streak in the market for a while. However, that seems to be changing, and in a big way. Last week, the price of the commodity started to find its way upward.




Of course, because Camber Energy focuses largely on natural gas liquids, it only makes sense that when the price of natural gas finds its way up, so too does the stock. After all, with the price of the commodity higher, the profits that CEI generates from the commodity climb.

From there, it was only a matter of traders. Essentially, traders realized that there were profits to be made surrounding the stock. With the idea of profits in the minds of traders, the gains ultimately became a self-fulfilling prophecy. As the profits continue to grow, traders continued pushing the value of the stock higher, leading to the overwhelmingly strong day the stock is enjoying thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on CEI and the natural gas sector as a whole. As we near winter time, demand for the commodity is only going to climb, which will likely translate into gains for the stock. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 627
CytRx Corporation CYTR Stock News

CytRx Corporation (NASDAQ: CYTR) is having a strong day in the market today. The gains seem to have started when a little known stock-related website appears to have started a takeover rumor. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:42), CYTR is trading at $0.61 per share after a gain of $0.02 per share (2.88%) thus far today.





Rumors Suggest That Roche Is Interested In CYTR

As mentioned above, CytRx Corporation is having a strong day in the market today after a little-known stock website released a rumor that the company would be acquired. The website (Sierra World Equity Review) released a short article saying that Roche has an offer on the table to acquire CYTR. Of course, as with most rumors, this one was abundantly vague. There was no mention of what the price of the acquisition might be, nor whether or not CYTR was interested in taking the offer. However, the article did mention that the reason for the potential acquisition is so that Roche can get their hands on aldoxorubicin.




Any time there is a takeover rumor in the market, it pays to be a skeptic. After all, very few of these rumors actually prove to be valid down the road. In this particular case, the rumor is most likely false. At the end of the day, if anyone was going to get their hands on a lead surrounding a takeover like this, if of course it was happening, it wouldn’t likely be Sierra World Review. The source of the rumor is not credible. As such, chances are that the rumor is just that… an invalid rumor. Nonetheless, that doesn’t mean that chances for a takeover are low by any means.

Will CYTR Be Acquired?

This leads us to the big question – will a CYTR acquisition actually happen? In my personal opinion, I will say that this is a very likely possibility. The reality is that CytRx Corporation is doing great things with aldoxorubicin. At the end of the day, aldoxorubicin is a new form of cancer treatment that addresses the illness in a different way than anything on the market. If you’d like to know more about the treatment, read this for all the info you will need.

At the end of the day CYTR is working to bring aldoxorubicin to market, and will be submitting its NDA for the treatment in the fourth quarter of this year. If all goes well, the treatment will be approved and become a massive driver of revenue for the company, or better yet, an acquisition will happen first.

The reality is that CytRx is in a prime position to be acquired. They have a promising treatment that’s got an NDA on the way in the oncology space. However, their market cap is relatively small, only around $80 million. With that in mind, this would be a relatively low-cost acquisition but would come with tremendous value thanks to aldoxorubicin.

So, has Roche made an offer? Chances are that the answer is no and the rumor is just a rumor. However, the big question is will an acquisition happen before aldoxorubicin approval? In my opinion, the chances of this are highly likely!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on CYTR. In particular, we’re interested in following the story surrounding aldoxorubicin and the possibility of an acquisition. We’ll continue to follow the news closely and bring it to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Amyris Inc AMRS Stock News

Amyris Inc (NASDAQ: AMRS) is off to an incredibly strong start to the trading session this morning, and for good reason. The company announced that it has entered into a product development and production agreement. Of course, this is leading to excitement among investors, causing gains and prompting our friends at Trade Ideas to alert us to the movement. At the moment (10:15), AMRS is trading at $3.64 per share after a gain of $0.25 per share (7.37%) thus far today.





AMRS Enters Product Development And Production Agreement

As mentioned above, Amyris is having a strong day in the market today after announcing that it has entered into its first product development and production agreement with Koninklijke DSM N.V. The company is a global science-based company active in the health, nutrition, and materials sector. The goal of the partnership is to develop a food and nutrition molecule for which DSM is a major market provider.




This comes shortly following a previously announced equity investment that DSM is making into AMRS. Part of this investment is that the companies have agreed to work together on several short- to medium-term product development and production opportunities and the vitamins and other nutritional ingredients industries. As such, the development and production agreement that was announced today is expected to be the first of several agreements to come.

Under this particular agreement, DSM has agreed to fund the development of the technology AMRS needs in order to produce the specific molecule. The molecule will be supplied long term through AMRS in order to provide improved performance. In a statement, John Melo, President and CEO at AMRS, had the following to offer:

We are very excited to partner with DSM on our first product development and production agreement… This is the first of what are expected to be several highly disruptive products addressing major markets where, together, we can leverage Amyris’s technology platform to reduce cost for products DSM then takes to market in a cost-advantaged position.”

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on AMRS. In particular, we’ll be watching the productivity surrounding the agreement that was announced today and we’re excited to learn of the new agreements that will be coming down the line relatively soon. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 181
AcelRx Pharmaceuticals Inc ACRX Stock News

AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) is having an incredibly strong day in the market today, and for good reason. A Seeking Alpha contributor wrote an article about the company, bringing a massive coming catalyst to light and causing excitement among investors. Of course, this led to gains in the stock, prompting our friends at Trade Ideas to alert us to the movement. At the moment (9:49), ACRX is trading at $3.00 per share after a gain of $0.60 per share (25.00%) thus far today.





ACRX Gains On Coming Catalyst

As mentioned above, AcelRx is having an incredibly strong day in the market today, and for good reason. A report on Seeking Alpha pointed out that the company is undervalued and has a massive catalyst on the horizon.




On the valuation side of the equation, the argument is a very simple one. While the company has an average price of under $3 per share, they have assets worth far more than that. In fact, the company actually has $1.59 per share in cash alone.

Perhaps most importantly, there are two big catalysts coming surrounding the stock. First and foremost, the company has a treatment known as Dsuvia that is pending approval by the FDA. The PDUFA date for this potential approval comes in October. On top of that, there’s Phase 3 data that will soon be released surrounding Zalviso. That data is expected to be released by the end of July. The value of these treatments, if they make it to the market, is incredibly high. In fact, it is estimated that ACRX could reach peak revenue from these treatments in the amount of $1.7 billion annually if all goes well.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on ACRX. In particular, we’re interested in following the two catalysts that will likely be hitting relatively soon. Both the FDA news surrounding Dsuvia in October and the data release that should be offered this month could lead to massive movement in the value of the stock. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Blue Apron Holdings Inc APRN Stock News

Blue Apron Holdings Inc (NYSE: APRN) is having a rough start to the day today in the pre-market hours after news broke that Amzon.com, Inc. (NASDAQ: AMZN) is continuing to work into the company’s industry. Through recent years, we’ve watched as Amazon has caused some serious industry disruption in the retail market, leading to the term “the Amazon effect” being coined. As is normally the case, our partners at Trade Ideas were the first to alert us to the losses. At the moment (9:24), APRN is trading at $6.87 per share after a loss of $0.49 per share or 6.66% thus far today.





APRN Is A Victim Of The Amazon Effect

As mentioned above, Blue Apron Holdings is having a rough day in the market as reports surface that Amazon is going to be getting into the company’s industry. At the moment, various reports are breaking out surrounding the idea that Amazon is making its way into the meal-kit delivery service, an industry that APRN has largely dominated through the years.




However, if there’s one thing that we know about AMZN, it’s that when the company gets involved in an industry, it quickly becomes a disruptive force. After all, the company is even giving WMT a run for their money.

The fear here for APRN investors is that Amazon will continue its record of success and dominate the meal-kit delivery industry shortly after they get into it. Of course, this would prove to be painful as it would ultimately cut into Blue Apron’s revenue.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will be keeping a close eye on both APRN and AMZN. After all, we’re interested in seeing what Amazon does with the meal-kit delivery industry and how it will effect Blue Apron. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 117
TherapeuticsMD Inc TXMD Stock News

TherapeuticsMD Inc (NYSEMKT: TXMD) is off to an incredibly rough start in the pre-market hours this morning, and for good reason. The company provided an update with regard to their activity with the United States Food and Drug Administration surrounding TX-004HR. Unfortunately, the update simply wasn’t what investors were expecting. In fact, Adam Feuerstein tweeted that the “update didn’t read well.” As a result, fear struck investors, leading to declines in the value of the stock and prompting our friends at Trade Ideas to alert us to the movement. At the moment (8:50), TXMD is trading at $5.00 per share after a loss of $0.63 per share (11.19%) thus far today.





TXMD Provides Regulatory Update

As mentioned above, TherapeuticsMD issued a PR today, updating investors with regard to conversations it’s having with the FDA surrounding TX-004HR. TX-004HR is the company’s investigational applicator-free estradiol vaginal softgel capsule for the treatment of moderate-to-severe vaginal pain during sexual intercourse.




In the PR, TXMD said that it participated in a Type A Post-Action Meeting with the Division of Bone, Reproductive, and Urologic Products of the United States Food and Drug Administration on Friday. The purpose of the meeting was to discuss the Complete Response Letter, or simply CRL, that was received surrounding the treatment. Through the meeting, TXMD said that it had presented new information that they believe could address concerns by the FDA in the CRL and possibly help to push TX-004HR to NDA approval.

In the PR, investors learned that TherapeuticsMD has received the minutes of the meeting, and upon the request of the FDA, has formally submitted the new information for consideration. The PR goes on to explain that productive dialogue is continuing with the FDA but there has not been a formal timeline offered with regard to the conclusion of the review. However, the most interesting line in the TXMD PR reads as follows:

The Company looks forward to working with the FDA to address its concerns regarding the NDA for TX-004HR and reserves the right to pursue the FDA’s formal dispute resolution process if a reasonable timeline to address such concerns cannot be established.”

With the line above, Feuerstein may have hit the nail on the head. The PR reads like there may be a hefty debate surrounding the TXMD CRL, one that could be a signal that the treatment isn’t going to be approved, or at least isn’t going to be approved any time soon.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on TXMD. In particular, we’re interested in following the company through the process of working to get TX-004HR to market. While things don’t look so great right now, anything can happen moving forward. We’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









0 190
How Longs Can Stop Shorts In The Stock Market

Have you ever seen a great piece of news on a stock, anticipated gains, and for some reason, that stock fell into the red? Have you followed a company that you know is doing amazing things in their industry, but for some reason, can’t seem to get ahead in the market? While there could be various reasons for this type of phenomenon, more often or not, the reason is that sell-side traders are attacking the stock by shorting it. Today, we’ll talk about what shorting a stock means, what needs to happen in order for a stock to be shorted, and what you can do about it if the shorts are attacking a stock that you care about!





What Does It Mean To Short A Stock?

Shorting a stock may seem like an overwhelmingly complex process. However, it’s actually a very simple one, once you know the inner workings of the process. You see, when a trader shorts a stock, he’s not necessarily buying it. In a way, that trader is selling the stock, but it goes a bit further than that.




You see, those who short stocks are essentially borrowing shares. These shares come from active accounts of those who are long on the stock. So, if you’re long, they are essentially borrowing your shares. From there, they sell the share in the market at the current price. Of course, if too many shares are sold, it leads to declines in the value of the stock.

Those who take part in this practice are looking for those declines. Remember, they have borrowed shares and sold them in the market at the price at which they borrowed them. The idea is that they will repurchase the shares later on at a lower price and give them back to those they borrowed them from. Of course, if all goes well for the short-side trader, he will make a profit because he was able to buy the stock for less money than he sold it for in the beginning. At the end, the short makes money, the long loses money, and in many cases, the long is none the wiser, wondering why the stock he has invested in is falling.

What Needs To Happen For Shorts To Make Money In This Process?

In order for those shorting a stock to make money in the process, only two things need to happen. First and foremost, they need to find shares to borrow. While they may not ask the longs, “Hey, can I borrow your shares so I can push their value down?”, they will go to brokers who lend shares under the noes of the longs, who have no idea it’s happening.

From there, the second thing that needs to happen is the price of the stock needs to fall. After all, the short seller is selling at the current price with a promise to return shares. If the price of the stock falls, there’s a spread where profit is created. However, if the price of the stock increases, those who are short on the stock will lose money when they have to repurchase the shares they borrowed at the higher cost.

What Longs Can Do To Stop The Manipulation

At the end of the day, without the longs, the shorts have absolutely nothing. While most longs have no idea that they can put a band aid on the bleeding wound, the truth of the matter is that they have all the power in the world since the shorts can’t complete the task without them.

If short selling is happening surrounding a stock that you care about it, there are two things that you can do to work to stop the bleeding. First and foremost, you’ll need to get on the phone with your broker. When you buy shares from a broker, it is automatically assumed in many cases that you are OK with your shares being borrowed. Call your broker and tell them that you are not. Lock those shares down so that the shorts can’t get hold of them.

The next thing that you can do is spread the word about how good of a company the company you’re invested in is. In doing so, the goal is to get more people buying shares, sending the value of the stock upward. This way, even the shorts that were able to buy shares take on a loss.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required









Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 5772
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...